ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0660

Improving the Gout Flare Chart Review Using Linked Claims-EHR Data
Abstract Number: 1073

In Favor of the Subspecialty Clinic Model for Rheumatoid Arthritis
Abstract Number: 1249

In Rheumatoid Arthritis, Inhibition of the Lactate Monocarboxylate Transporters-1, and -4 in Pathological Fibroblast-Like Synoviocytes Led to Decreased ChemokineProduction
Abstract Number: 0200

In Undifferentiated Arthritis, DMARD-treatment Intensified During the Last Decennia but Did Not Result in Improved Outcomes
Abstract Number: 1928

In Vitro and In Vivo Evidence for DOCK8 as a Risk Allele for Cytokine Storm Syndrome, Including COVID-19 and MIS-C
Abstract Number: 1406

Incidence and General Clinical Features of Giant Cell Arteritis in the ARTESER Multicenter Study
Abstract Number: 1022

Incidence of Antisynthetase Syndrome and Risk of Malignancy in a Population-based Cohort (1998-2019)
Abstract Number: 1684

Incidence of Infections in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Abstract Number: 1865

Incidence, Prevalence, and Mortality of Chronic Periaortitis: A Population-based Study
Abstract Number: 0689

Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-based Cohort
Abstract Number: 1466

Increased Adverse Maternal Postpartum Outcomes in Systemic Lupus Erythematosus Pregnancies Compared to Controls
Abstract Number: 1659

Increased All-Cause Mortality Risk in Patients with Incident Rheumatoid Arthritis After First Antidepressant Dispensing: Results from the Nationwide DANBIO Database
Abstract Number: 0019

Increased Circulating CD39+FoxP3+CD4+ Treg Cells in Early Rheumatoid Arthritis Facilitate the Antiinflammatory Action of Methotrexate
Abstract Number: 1643

Increased Incidence of Pediatric SLE and Other Interferon Activated Diseases During COVID-19 Pandemic
Abstract Number: 1907

Increased Otoferlin Expression in B Cells Is Associated with Muscle Weakness in Untreated Juvenile Dermatomyositis: A Pilot Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].